Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Go back to Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
(NASDAQ: EDSA) Delayed: 2.59 -0.18 (6.5%)
Previous Close $2.77    52 Week High $ 
Open $2.70    52 Week Low $ 
Day High $2.74    P/E N/A 
Day Low $2.54    EPS $ 
Volume 63,801